Other Financial Information

Accrued expenses at December 31, 2015 and 2014 consisted of the following:



	2015		2014
Compensation	$	297.8	$	285.2
Rebates, distributor chargebacks and distributor services	365.5		232.9
Clinical trial costs and grants	255.1		189.5
Interest	170.3		59.1
Royalties, license fees and collaboration agreements	75.9		26.7
Commercial related activities	38.7		56.2
Sales returns	18.8		10.2
Rent	18.1		14.0
Professional services	14.9		7.9
Other taxes	7.9		9.3
Other	113.7		100.1
Total	$	1,376.7	$	991.1

Other current liabilities at December 31, 2015 and 2014 consisted of the following:



	2015		2014
Deferred tax liability	$	—	$	131.2
Contingent consideration – Quanticel acquisition	82.5		—
Contingent consideration – Nogra acquisition	24.9		24.7
Contingent consideration – Avila acquisition	2.0		9.8
Compensation	55.6		32.6
Sales, use and value added tax	61.1		56.8
Derivative contracts	4.5		2.6
Collaboration agreement upfront payable	40.3		14.0
Other	0.1		4.1
Total	$	271.0	$	275.8

Other non-current liabilities at December 31, 2015 and 2014 consisted of the following:



	2015		2014
Contingent consideration – Quanticel acquisition	$	84.2	$	—
Contingent consideration – Nogra acquisition	1,214.5		1,110.8
Contingent consideration – Avila acquisition	94.5		114.2
Contingent consideration – Gloucester acquisition	18.9		19.5
Contingent Value Rights - Abraxis acquisition	51.9		136.3
Deferred compensation and long-term incentives	170.5		150.5
Deferred tax liability	377.7		555.6
Other	29.5		49.8
Total	$	2,041.7	$	2,136.7